Report Code: TIPRE00003012 | No. of Pages: 150 | Category: Medical Device | Status: Prebook
The increasing number of patients suffering from diabetes, asthma, hypertension, tuberculosis, multiple sclerosis, clinically isolated syndrome, chronic obstructive pulmonary disease (COPD), hepatitis C, and other chronic diseases and the growing emphasis of healthcare professionals on preventive care drive the growth of the connected drug delivery devices market. Connected drug delivery devices are made by using embedded electronics and sensors. The devices are designed to collect information on self-administration and transmit real-time dose compliance data from the device to the patient’s smartphone and the HCP’s database. As a result of drug delivery connectivity, the remote compliance helps highlight potential complications that could lead to poor treatment outcomes. During COVID-19 outbreak, patients were restricted from visiting hospitals to avoid the spread of the virus infection. Thus, to maintain social distancing, patients and healthcare professionals depended on self-administration and remote monitoring.
|Market Size Value in||US$ 463.59 Million in 2021|
|Market Size Value by||US$ 7,998.09 Million by 2028|
|Growth rate||CAGR of 50.3% from 2022 to 2028|
|No. of Pages||150|
|Historical data available||Yes|
|Segments covered||Type, Technology, End User, and Geography|
|Regional scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Country scope||US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
From the regional perspective, North America dominates the connected drug delivery devices market with ~35% market share in 2021. Rising per capita expenditure of healthcare and the increasing adoption of advances in product launches and related innovations bolster the growth of the regional market. The below figure shows the revenue growth trend in the connected drug delivery devices market:
Source: The Insight Partners Analysis
The report analyzes factors, such as drivers, restraints, opportunities, and future trends, which impact the connected drug delivery devices market. It also provides an exhaustive Porter's five forces analysis of the factors influencing the market.
During COVID-19 outbreak, the demand for connected drug delivery devices increased, which led to a high volume of orders among drug manufacturers, resulting in a higher production volume of connected sensors. Thus, owing to the COVID-19 crisis and the transition of individuals and healthcare professionals to adopt remote patient monitoring methods have bolstered the demand for connected drug delivery devices at the recent past. The trend is expected to continue during the forecast period.
The report includes the profiles of key connected drug delivery devices market companies, along with their SWOT analysis and market strategies. In addition, it focuses on leading industry players’ company profiles, components and services offered, financial information for the last three years, and key developments in the past five years. The list of a few companies engaged in the connected drug delivery devices market is mentioned below:
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
The List of Companies
2. West Pharma
3. Aterica Inc.
4. Panasonic Corporation
6. Merck KGaA
7. Propeller Health
8. Proteus Digital Health
9. Adherium Limited
10. Qualcomm Technologies, Inc.